Occludin Antibody - #DF7504

(131)   (90)  
Product: Occludin Antibody
Catalog: DF7504
Description: Rabbit polyclonal antibody to Occludin
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat, Pig
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog, Chicken
Mol.Wt.: 23~30kD, 52~65kD; 59kD(Calculated).
Uniprot: Q16625
RRID: AB_2841004

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IHC 1:50-1:200, IF/ICC 1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat,Pig
Prediction:
Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(80%)
Clonality:
Polyclonal
Specificity:
Occludin Antibody detects endogenous levels of total Occludin.
RRID:
AB_2841004
Cite Format: Affinity Biosciences Cat# DF7504, RRID:AB_2841004.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

BLCPMG; FLJ08163; FLJ18079; FLJ77961; FLJ94056; MGC34277; Occludin; Ocln; OCLN_HUMAN; Tight junction protein occludin;

Immunogens

Immunogen:
Uniprot:

Q16625(OCLN_HUMAN) >>Visit HPA database.

Gene(ID):
OCLN(100506658)
Expression:
Q16625 OCLN_HUMAN:

Localized at tight junctions of both epithelial and endothelial cells. Highly expressed in kidney. Not detected in testis.

Sequence:
MSSRPLESPPPYRPDEFKPNHYAPSNDIYGGEMHVRPMLSQPAYSFYPEDEILHFYKWTSPPGVIRILSMLIIVMCIAIFACVASTLAWDRGYGTSLLGGSVGYPYGGSGFGSYGSGYGYGYGYGYGYGGYTDPRAAKGFMLAMAAFCFIAALVIFVTSVIRSEMSRTRRYYLSVIIVSAILGIMVFIATIVYIMGVNPTAQSSGSLYGSQIYALCNQFYTPAATGLYVDQYLYHYCVVDPQEAIAIVLGFMIIVAFALIIFFAVKTRRKMDRYDKSNILWDKEHIYDEQPPNVEEWVKNVSAGTQDVPSPPSDYVERVDSPMAYSSNGKVNDKRFYPESSYKSTPVPEVVQELPLTSPVDDFRQPRYSSGGNFETPSKRAPAKGRAGRSKRTEQDHYETDYTTGGESCDELEEDWIREYPPITSDQQRQLYKRNFDTGLQEYKSLQSELDEINKELSRLDKELDDYREESEEYMAAADEYNRLKQVKGSADYKSKKNHCKQLKSKLSHIKKMVGDYDRQKT

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Rabbit
100
Chicken
80
Xenopus
67
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q16625 As Substrate

Site PTM Type Enzyme
S8 Phosphorylation
K18 Ubiquitination
S40 Phosphorylation
Y44 Phosphorylation
S45 Phosphorylation
K276 Ubiquitination
S277 Phosphorylation
K283 Ubiquitination
Y287 Phosphorylation
K299 Ubiquitination
S302 Phosphorylation
T305 Phosphorylation
S310 Phosphorylation
S313 Phosphorylation
Y315 Phosphorylation
S321 Phosphorylation
Y325 Phosphorylation
S326 Phosphorylation
S327 Phosphorylation
K330 Ubiquitination
Y337 Phosphorylation
S340 Phosphorylation
S341 Phosphorylation
Y342 Phosphorylation
K343 Ubiquitination
S344 Phosphorylation
T345 Phosphorylation
S358 Phosphorylation
Y368 Phosphorylation
S369 Phosphorylation
S370 Phosphorylation
T376 Phosphorylation
S378 Phosphorylation
K379 Ubiquitination
T393 Phosphorylation
Y398 Phosphorylation P12931 (SRC)
T400 Phosphorylation P68400 (CSNK2A1)
Y402 Phosphorylation P12931 (SRC)
T403 Phosphorylation Q02156 (PRKCE) , P24723 (PRKCH) , Q05513 (PRKCZ)
T404 Phosphorylation Q02156 (PRKCE) , Q05513 (PRKCZ) , P24723 (PRKCH) , P68400 (CSNK2A1) , P67870 (CSNK2B)
S408 Phosphorylation P67870 (CSNK2B) , P68400 (CSNK2A1)
T424 Phosphorylation Q02156 (PRKCE) , Q05513 (PRKCZ)
T438 Phosphorylation Q02156 (PRKCE) , Q05513 (PRKCZ)
Y443 Phosphorylation
S445 Phosphorylation
S448 Phosphorylation
S458 Phosphorylation
Y467 Phosphorylation
S471 Phosphorylation
Y474 Phosphorylation
Y481 Phosphorylation
K488 Ubiquitination
S490 Phosphorylation P05771 (PRKCB)

Research Backgrounds

Function:

May play a role in the formation and regulation of the tight junction (TJ) paracellular permeability barrier. It is able to induce adhesion when expressed in cells lacking tight junctions.

PTMs:

Dephosphorylated by PTPRJ. The tyrosine phosphorylation on Tyr-398 and Tyr-402 reduces its ability to interact with TJP1. Phosphorylation at Ser-490 also attenuates the interaction with TJP1.

Subcellular Location:

Cell membrane>Multi-pass membrane protein. Cell junction>Tight junction.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Localized at tight junctions of both epithelial and endothelial cells. Highly expressed in kidney. Not detected in testis.

Subunit Structure:

Interacts with TJP1/ZO1. Interacts with VAPA. Interacts with CLDN1, CLDN6, CLDN9, CLDN11, CLDN12 and CLDN17.

Family&Domains:

The C-terminal is cytoplasmic and is important for interaction with ZO-1. Sufficient for the tight junction localization. Involved in the regulation of the permeability barrier function of the tight junction (By similarity). The first extracellular loop participates in an adhesive interaction.

Belongs to the ELL/occludin family.

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Tight junction.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cell adhesion molecules (CAMs).   (View pathway)

· Human Diseases > Infectious diseases: Bacterial > Pathogenic Escherichia coli infection.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Organismal Systems > Immune system > Leukocyte transendothelial migration.   (View pathway)

References

1). Gingerenone A Attenuates Ulcerative Colitis via Targeting IL-17RA to Inhibit Inflammation and Restore Intestinal Barrier Function. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024 (PubMed: 38639442) [IF=15.1]

Application: IF/ICC    Species: Mouse    Sample:

Figure 2. GA suppressed inflammation and protected against intestinal barrier dysfunction to attenuate colitis in mice. A) Inflammatory cytokines (IL‐1β, IL‐6, IL‐17, and TNF‐α) levels in colonic tissues (n = 6). B) Inflammatory cytokines (IL‐1β, IL‐6, IL‐17, and TNF‐α) levels in serum (n = 6). C) MPO activity in colonic tissues (n = 6). D,E) NIMP‐R14 positive expression level, and representative IHC pictures of NIMP‐R14 protein (n = 6). F) Representative immunofluorescence images of ZO‐1, Occludin, and Muc‐2 in colonic tissues (n = 3). G) Serum FD4 level (n = 6) and the fluorescence intensities of ZO‐1, Occludin, and Muc‐2 (n = 3). H) Pearson correlation heatmap circos among pro‐inflammation cytokines levels, intestinal barrier function proteins, and pharmacodynamic evaluation index in different groups (n = 3). All data are expressed as mean ± S.E.M. *P < 0.05 and **P < 0.01 compared with the control group (Ctrl), #P < 0.05 and ## P < 0.01 compared with the DSS group.
2). Extracellular vesicles of Fusobacterium nucleatum compromise intestinal barrier through targeting RIPK1-mediated cell death pathway. Gut Microbes, 2021 (PubMed: 33769187) [IF=12.2]

Application: IHC    Species: mouse    Sample: colon

Figure 5. |FnEVs increase gut barrier leakage in experimental colitis models. (a) Representative images and ex vivo imaging with the intestine, liver, heart, spleen and kidney of mice. (b) Relative fluorescence intensity of translocated EGFP-labeled E.coli in every tissues. (c) Representative images of immunohistochemical stainings of ZO-1, claudin-1 and occludin in the colon on day 3 after colitis induction. Scale bar = 50 um.
3). Water-extracted Lonicera japonica polysaccharide attenuates allergic rhinitis by regulating NLRP3-IL-17 signaling axis. Carbohydrate Polymers, 2022 (PubMed: 36184153) [IF=10.7]
4). Vitamin K1 ameliorates lipopolysaccharide-triggered skeletal muscle damage revealed by faecal bacteria transplantation. Journal of cachexia, sarcopenia and muscle, 2024 (PubMed: 38018317) [IF=9.4]

Application: WB    Species: Mouse    Sample:

Figure 2 Faecal bacteria transplantation from S‐res mice alleviates LPS‐triggered muscle damage and intestinal barrier disruption. (A) Description of the steps of FMT experiment. (B) The score for Severity of sepsis in Sen and Res. (C) H&E staining in the GA muscle. Representative histological images on day 9 postoperatively (400× magnification). Scale bar = 100 μm. Comparison of muscle fibre diameter and CSA of muscle fibre in mice from each group. (D) Western blot analysis of MuRF‐1 and MAFbx protein levels in TA tissue in Sen and Res groups. The results were normalized to the expression of GAPDH. (E) Western blot analysis of ZO‐1 and occludin protein levels in colon tissue in Sen and Res groups. The results were normalized to the expression of GAPDH. Data are means ± SEM. P values determined through Student's t test and ordinary one‐way ANOVA. Sen versus Res: # P < 0.05, ## P < 0.01, ### P < 0.001. Sen and Res versus Ctrl: **P < 0.01, ***P < 0.001. Sen versus ABX: $ P < 0.05.
5). Intestinal homeostasis disrupted by Periodontitis exacerbates Alzheimer's Disease in APP/PS1 mice. Journal of neuroinflammation, 2024 (PubMed: 39425119) [IF=9.3]
6). Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism. npj Biofilms and Microbiomes, 2023 (PubMed: 37258543) [IF=9.2]
7). Gut microbiota-mediated secondary bile acid alleviates Staphylococcus aureus-induced mastitis through the TGR5-cAMP-PKA-NF-κB/NLRP3 pathways in mice. npj Biofilms and Microbiomes, 2023 (PubMed: 36755021) [IF=9.2]
8). Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-κB pathway. PHARMACOLOGICAL RESEARCH, 2020 (PubMed: 31863867) [IF=9.1]

Application: WB    Species: Mice    Sample: colonic tissues

Fig. 4. OBB protected intestinal epithelial barrier by modulating TJs proteins. Effect of OBB on the mRNA levels of mucin-1(A) and mucin-2 (B). (C) Representative Western blotting images of TJs protein, and the relative protein expressions were normalized to β-actin. (D-H) Changes in the relative protein expression levels of ZO-1, ZO-2, occludin, JAM-A, and claudin-1 were measured respectively. Data are shown as mean ± SEM (n = 3). # P < 0.05, ## P < 0.01 vs. Control group, * P < 0.05, ** P < 0.01 vs. DSS group, & P < 0.05, && P < 0.01 vs. BBR group.
9). Fourteen composite probiotics alleviate type 2 diabetes through modulating gut microbiota and modifying M1/M2 phenotype macrophage in db/ db mice. PHARMACOLOGICAL RESEARCH, 2020 (PubMed: 32818655) [IF=9.1]

Application: IHC    Species: mouse    Sample: colon

Fig. 4.| Effects of the composite probiotics on intestinal barrier function.The protein expression of claudin-1 (G), occludin-1 (H), ZO-1 (I) and mucin-2 (J)determined by immunohistochemistry (original magnification 200×) (n = 4 images/group).
10). Multistage-Responsive Nanocomplexes Attenuate Ulcerative Colitis by Improving the Accumulation and Distribution of Oral Nucleic Acid Drugs in the Colon. ACS Applied Materials & Interfaces, 2022 (PubMed: 34978415) [IF=8.3]
Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.